Executives share insights at recent conferences.
Held for the first time in person the second week of October, Reuters Pharma 2022 in Nice, France brought a lot of energy and excitement back to this staple European event, previously produced by eyeforpharma and held annually in Barcelona. The event will make a return to Barcelona, and back to its traditional spring schedule next year.
What makes this conference a must is the ex-US pharma factor, and the whole reason for pharma’s need for global presence and expertise in market access, patient centricity, and healthcare professional (HCP) approaches.
The actual running of a pharma company or division has a universal approach. Executives presenting at the conference shared similar views on the needs for pharma achievement in the near-term. These include agile planning—the need to move those decisions from the traditional 18 months to 90 days; a simplified but more robust engagement model; and the agility to pivot from ways and strategies that don’t work anymore, and moving resources to those that do.
Highlights from the sessions: digital therapeutics, virtual reality, digital twins; integrating the patient voice has changed 100% of clinical trials and 45% of protocols at one pharma; a small pilot using AI to detect potential lung cancer in any imaging/chest x-rays performed to treat that cancer earlier and more efficiently; using data to predict a pain crisis common in sickle cell patients at higher risk for organ failure; and many insights on real-world evidence (RWE).
Again, the chance to learn from initiatives across Europe, some that transcend geography, and others that create opportunities out of local regulations, is for these attendees a true sharing event.
Another first in-person event that took place in October was our own second-annual Pharmaceutical Executive APEX Awards. After going virtual our first year, the second event was tastefully and beautifully executed in Gotham Hall, NYC by our MJH Life Sciences Live Events team.
We could only share a few photos, along with the list of winners, but be assured it was a great event. As the only healthcare awards show judged entirely by HCPs, the awards go to creative agency campaigns submitted for pharmaceutical marketing in a variety of therapeutic categories. We hope to see you there in 2023!
Lisa Henderson is Pharm Exec’s Group Editorial Director. She can be reached at lhenderson@mjhlifesciences.com.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.